
Pharmacally
ICOTYDE
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in ICOTYDE
Clinical TrialsICOTYDE Sustains PASI 90 Response Through Two YearsJohnson & Johnson reports two-year Phase 3 ICONIC-LEAD results for ICOTYDE (icotrokinra), showing sustained PASI 90 responses, continued itch improvement and no new safety signals through Week 112…Fact-Checked
Clinical TrialsICONIC-TOTAL Reports 2-Year ICOTYDE Data Showing Sustained Psoriasis ClearanceJohnson & Johnson reports two-year ICONIC-TOTAL data showing sustained skin clearance with ICOTYDE (icotrokinra) in difficult-to-treat plaque psoriasis.Fact-Checked
Health TidingsAfter FDA Approval, J&J Shows Durable 52-Week ICOTYDE Results in PsoriasisNew 52-week data presented at AAD 2026 show ICOTYDE maintains strong skin clearance and a consistent safety profile, supporting its recent FDA approval in plaque psoriasis.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.